Clinical Trial

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety/feasibility study of the investigational procedure/product.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-02-09; most recent amendment 2026-03-31.
Status change: Not Yet Recruiting → Recruiting 2023-05-12
Trial Details
NCT Number NCT05735717
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21 +16 more
Enrollment 70 participants
Start Date 2023-05-11
Primary Completion 2027-11-30 (estimated)
Study Completion 2030-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-06